Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6

Wells Fargo analyst Yanan Zhu has upgraded Editas Medicine (NASDAQ: EDIT) from Equal-Weight to Overweight. The price target for the stock has been raised from $4 to $6.